Swanrose plans to launch five products in health, hygiene segment

New Delhi: Betting on the health and hygiene segmentSwanrose India on Thursday launched a new hand sanitiser and plans to expand its portfolio in the coming months, according to a company official. It plans to introduce five products in the health and hygiene segment this year and is also looking to enter the South America and the Middle East markets.

The company is a wholly-owned subsidiary of US-based Swanrose Inc.

On Thursday, the company introduced the hand sanitiser under the brand name ‘Just Human‘ in India and the US markets simultaneously, claiming that it will protect the users 24 hours from getting infected with coronavirus.

Swanrose Inc CEO Roshini Sanah Jaiswal said, “it is the first hand sanitiser to provide extended protection. The 24-hour efficacy is backed by GLP Lab certification”

‘Just Human’ 24-hour hand sanitiser is made in India with proprietary US technology. The product has got USFDA registration and DCGI clearance in India, she added.

Presently, the company is getting its hand sanitiser manufactured here through a third party contract manufacturer from Punjab.

Initially, the company expects monthly sales of 1.5 crore from the Indian market.

“We are not one product company. Our vision is to grow,” she said, adding a couple of products are at the R&D stage, which will be intellectual property-protected products.

Swanrose started business in April 2020, by producing alcohol-based hand sanitisers. The first product launch was Aristocrat and Humaste, both alcohol-based hand sanitisers, in India and the USA.

Roshini Sanah Jaiswal is also the promoter and Chief Restructuring Officer of the Delhi-based liquor company Jagatjit Industries.

  • Related Posts

    Madras HC Refuses To Quash FIR In Counterfeit Drug Case, Orders CBI To Complete Probe In 12 Weeks

    CHENNAI: The Madras High Court on Friday dismissed a petition seeking to quash a First Information Report (FIR) registered against Puducherry-based pharmaceutical entities accused of manufacturing and distributing counterfeit medicines…

    Chhattisgarh draws Rs 992.53 Cr worth pharma investment proposals in 18 months

    Chhattisgarh: Riding on policy reforms that earned it the top rank among large states in NITI Aayog’s Investment Friendliness Index 2026 for Regulatory Ease and Institutional Environment, Chhattisgarh has received…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Madras HC Refuses To Quash FIR In Counterfeit Drug Case, Orders CBI To Complete Probe In 12 Weeks

    Madras HC Refuses To Quash FIR In Counterfeit Drug Case, Orders CBI To Complete Probe In 12 Weeks

    Chhattisgarh draws Rs 992.53 Cr worth pharma investment proposals in 18 months

    Chhattisgarh draws Rs 992.53 Cr worth pharma investment proposals in 18 months

    FSSAI suspends license of Punjab-based Rehaan Healthcare for breach of norms at manufacturing unit

    FSSAI suspends license of Punjab-based Rehaan Healthcare for breach of norms at manufacturing unit

    Pharma companies in a flux over Trump’s 200% tariff move on generics

    Pharma companies in a flux over Trump’s 200% tariff move on generics

    Noida Raid Uncovers Suspected ₹2.48-Crore Diversion of Life-Saving Medicines; Probe Expands Into Government Supply Chain and Interstate Network

    Noida Raid Uncovers Suspected ₹2.48-Crore Diversion of Life-Saving Medicines; Probe Expands Into Government Supply Chain and Interstate Network

    CDSCO Directs Safety Updates for Ibuprofen and Aceclofenac Over Risk of ‘Fixed Drug Eruption’

    CDSCO Directs Safety Updates for Ibuprofen and Aceclofenac Over Risk of ‘Fixed Drug Eruption’